BPC-157 vs GHK-Cu
One is an injected research peptide with no human trials; the other is a copper tripeptide whose usable human evidence is topical and cosmetic. Route decides almost everything.
Short answer
BPC-157 and GHK-Cu are both graded preclinical / minimal, which leaves little or no controlled human data to choose between them. What does differ is access, since BPC-157 is sold gray-market as a research chemical, while GHK-Cu is sold in cosmetic skin-care products. BPC-157 is the one sold for healing, recovery and gut health, while GHK-Cu targets skin and hair.
BPC-157
Almost entirely animal data; no validated human dose and no controlled efficacy trials.
Full BPC-157 evidence reviewGHK-Cu
Copper tripeptide
Real tissue-remodeling biology, mostly in-vitro and topical; a cosmetic signal, not systemic anti-aging proof.
Full GHK-Cu evidence reviewBPC-157 vs GHK-Cu: head to head
- FDA status / approved use
BPC-157
Not an approved drug anywhere; typically sold labeled for research use onlyGHK-Cu
Long-established cosmetic ingredient in skincare creams and serums- Marketed for
BPC-157
Healing, recovery, gut healthGHK-Cu
Skin, hair, 'anti-aging'- Outcome areas
BPC-157
Injury recovery / tissue repair; Gut healthGHK-Cu
Skin / hair; Longevity / lifespan- Evidence grade
BPC-157
Preclinical / minimalGHK-Cu
Preclinical / minimal- How it works
BPC-157
Appears to act on multiple repair pathways, including nitric-oxide and vascular systemsGHK-Cu
Copper-binding tripeptide that stimulates collagen synthesis in lab studies- Route and dosing
BPC-157
Injection; no established human doseGHK-Cu
Topical cream or serum; injected forms are also sold- Headline human result
BPC-157
Not establishedGHK-Cu
Not established- Strongest evidence
BPC-157
Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317GHK-Cu
J Biomater Sci, 2008. Little or no controlled human outcome data for the marketed useGHK-Cu evidence reviewPubMed 18644225- Key safety signal
BPC-157
No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risksGHK-Cu
Injected form has no established dosing or long-term safety data; copper can be toxic in excess- How it is obtained
BPC-157
Sold gray-market as a research chemical; no approved or legitimately compounded human productGHK-Cu
Sold in cosmetic skin-care products
| BPC-157 | GHK-Cu | |
|---|---|---|
| FDA status / approved use | Not an approved drug anywhere; typically sold labeled for research use only | Long-established cosmetic ingredient in skincare creams and serums |
| Marketed for | Healing, recovery, gut health | Skin, hair, 'anti-aging' |
| Outcome areas | Injury recovery / tissue repair; Gut health | Skin / hair; Longevity / lifespan |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Appears to act on multiple repair pathways, including nitric-oxide and vascular systems | Copper-binding tripeptide that stimulates collagen synthesis in lab studies |
| Route and dosing | Injection; no established human dose | Topical cream or serum; injected forms are also sold |
| Headline human result | Not established | Not established |
| Strongest evidence | Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317 | J Biomater Sci, 2008. Little or no controlled human outcome data for the marketed useGHK-Cu evidence reviewPubMed 18644225 |
| Key safety signal | No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks | Injected form has no established dosing or long-term safety data; copper can be toxic in excess |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold in cosmetic skin-care products |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
These are not interchangeable, and the evidence quality is not close in the way people assume. BPC-157's record is rodent and cell-culture work; there are no published randomized controlled trials in humans for any indication, no established dose, and it is not an approved drug anywhere, with the FDA having flagged it as ineligible for compounding pharmacies in 2023. GHK-Cu has a decades-deep mechanistic literature plus some human data, but that human data is small cosmetic-grade studies of topical copper-peptide creams reporting improvements in skin appearance, which is not a tissue-repair outcome; injected GHK-Cu has no human efficacy trials, no established dosing, and copper can be toxic in excess. The two have never been compared directly, and if your goal is healing a tendon or a gut lining, neither has human outcome evidence to offer.
BPC-157 fits if
Someone tracking soft-tissue and gastrointestinal repair biology as a research topic, who understands every claim is extrapolated from rodents using an unapproved, research-only product.
GHK-Cu fits if
Someone who wants a skin ingredient with a plausible collagen-remodeling mechanism and a benign topical safety record, and who stays in the cream rather than the syringe.
BPC-157 vs GHK-Cu: common questions
- Is either BPC-157 or GHK-Cu FDA-approved?
- No. BPC-157 is not an approved drug anywhere; typically sold labeled for research use only. GHK-Cu is a long-established cosmetic ingredient in skincare creams and serums.
- Which has stronger human evidence, BPC-157 or GHK-Cu?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for BPC-157 is Pharmaceutics review, 2026; for GHK-Cu, it is J Biomater Sci, 2008.
- What are the main safety concerns with BPC-157 and GHK-Cu?
- BPC-157 has no human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks. With GHK-Cu, injected form has no established dosing or long-term safety data; copper can be toxic in excess.
Key studies behind each
BPC-157
- Sikiric P, Sever M, Krezic I, et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PubMed 38980576
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Bilic Z, Gojkovic S, Kalogjera L, et al. (2021). Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach through modulation of the nitric-oxide system. J Physiol Pharmacol. PubMed 35485358
GHK-Cu
- Pickart L. (2008). The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. PubMed 18644225
- Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. PubMed 26236730
- Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PubMed 29986520
- Dou Y, Lee A, Zhu L, et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. PubMed 35083444
The full evidence reviews
- BPC 157: what the evidence actually shows (and what it doesn't)
The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.
Updated October 2026
- GHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm BPC-157 availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Always Wellness and RecoveryAmbiante Health & WellnessBlis MDCalifornia Trim ClinicClinic SecretDr. Gillis' Wellness Center